<DOC>
	<DOCNO>NCT00336362</DOCNO>
	<brief_summary>Beta thalassemia major serious genetic disease blood . Treatments limit , although bone marrow transplant compatible donor curative , limited percentage individual disease match donor available . A long-term goal study researcher develop gene transfer process method cure beta thalassemia major . Gene transfer involve obtain blood stem cell individual , add normal globin gene stem cell , put cell back individual . Before gene transfer method attempt individual beta thalassemia major , safe method obtain blood stem cell need develop . The purpose study investigate safety feasibility collect peripheral blood stem cell ( PBSC ) individual beta thalassemia major . Research participant give G-CSF ( filgrastim ) several day increase number stem cell blood , process call `` mobilization . '' After mobilization , participant undergo procedure call apheresis remove white blood cell . Researchers laboratory purify stem cell mixture test method put normal globin gene stem cell . Half participant receive hydroxyurea ( HU ) prior G-CSF mobilization . HU use splenectomized patient attempt reduce risk clot mobilization . In non-splenectomized patient , HU give attempt decrease size spleen .</brief_summary>
	<brief_title>Evaluating Safety G-CSF Mobilization Individuals With Beta Thalassemia Major</brief_title>
	<detailed_description>Primary Objective : To determine safety PBSC mobilization G-CSF , without HU pretreatment adult beta thalassemia major . Secondary Objective : To determine number CD34+ stem/progenitor cell mobilize condition , well ability cell transduce recombinant lentivirus vector beta-globin engraft immunodeficient mouse . Study Design : The ability G-CSF safely effectively mobilize PBSC adult beta thalassemia major assess 12 splenectomized 12 non-splenectomized patient . Of 12 splenectomized patient , 6 treat HU G-CSF , 6 treat G-CSF . Likewise , 12 non-splenectomized patient , 6 treat HU G-CSF , 6 treat G-CSF . G-CSF mobilize participant undergo leukapheresis 2 consecutive day , target yield 2 million CD34+ cell per kg body weight . Safety assess monitor study-related toxicity . Efficacy assess measure total number CD34+ cell , ability cell transduce recombinant lentivirus vector beta-globin , ability cell engraft immunodeficient mouse . Population : Adults beta thalassemia major . Sample size : A total 24 subject enrol : 12 splenectomized participant 12 non-splenectomized participant . End Points : This pilot study specific hypothesis test . However , study allow qualitative comparison outcomes various arm markedly different . For example , study provide qualitative data safety feasibility utilize HU G-CSF mobilize stem cell individual beta thalassemia major . The study complete upon full enrollment , stop criterion meet within specific study arm .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>βthalassemia major Karnofsky performance status great equal 80 % Splenectomized patient patient spleen volume le 800 cm^3 ( V=0.523 x length x thickness x width ) Compliant regular transfusion regular chelation Liver iron magnetic resonance imaging ( MRI ) less 280 μmol/gr great equal 1.7 msec T2*MRI Heart iron MRI great 2.8 ( SI/SD ) great equal 9 msec T2*MRI Hepatitis B C virus load negative polymerase chain reaction ( PCR ) Left ventricular ejection fraction ( LVEF ) great 45 % echocardiogram multiple gate acquisition scan ( MUGA ) Adequate respiratory function diffuse capacity lung carbon monoxide ( DLCO ) great 50 % Negative pregnancy test , female Ability give inform consent willingness meet expect requirement protocol duration study History thrombosis know thrombophilia Symptomatic viral , bacterial , fungal infection within 6 week eligibility evaluation Pregnant breastfeeding HIV positivity History cancer , local skin cancer Other systematic disease Splenectomized patient platelet count great 900,000 Additional risk factor thrombosis , include Factor V Leiden ; antiphospholipid antibody ; le 50 % low normal value follow procoagulants : antithrombin 3 , protein C , protein S</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Beta Thalassemia Major</keyword>
	<keyword>Hematopoietic Stem Cell Mobilization</keyword>
	<keyword>Gene Transfer Techniques</keyword>
</DOC>